Population Health Sciences

You are here

Home > Publications > Publications

Publications

Found 41 results
[ Author(Desc)] Title Type Year
Filters: First Letter Of Last Name is M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
M
Meinhofer A, Williams ARobin, Johnson P, Schackman BR, Bao Y.  2019.  Prescribing decisions at buprenorphine treatment initiation: Do they matter for treatment discontinuation and adverse opioid-related events? J Subst Abuse Treat. 105:37-43.
Meinhofer A.  2020.  Pediatric Implications of Opioid-Specific Parental Drug Use-Reply.. JAMA Pediatr.
Meisel ZF, Mitchell J, Polsky D, Boualam N, McGeoch E, Weiner J, Miclette M, Purtle J, Schackman B, Cannuscio CC.  2019.  Strengthening partnerships between substance use researchers and policy makers to take advantage of a window of opportunity.. Subst Abuse Treat Prev Policy. 14(1):12.
Merkler AE, Parikh NS, Mir S, Gupta A, Kamel H, Lin E, Lantos J, Schenck EJ, Goyal P, Bruce SS et al..  2020.  Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza.. JAMA Neurol.
Min JY, Simmons W, Banerjee S, Wang F, Williams N, Zhang Y, Reese AB, Mushlin AI, Flory JH.  2022.  Association between antidiabetic drug use and the risk of COVID-19 hospitalization in the INSIGHT Clinical Research Network in New York City.. Diabetes Obes Metab. 24(7):1402-1405.
Min JYoung, Williams N, Simmons W, Banerjee S, Wang F, Zhang Y, Reese AB, Mushlin AI, Flory JH.  2022.  Baseline haemoglobin A1c and the risk of COVID-19 hospitalization among patients with diabetes in the INSIGHT Clinical Research Network.. Diabet Med. 39(5):e14815.
Molina AM, van der Mijn JC, Christos P, Wright J, Thomas C, Dutcher JP, Nanus DM, Tagawa ST, Gudas LJ.  2020.  NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma.. Invest New Drugs.
Mones E, Stopczynski A, Pentland A'Sandy', Hupert N, Lehmann S.  2018.  Optimizing targeted vaccination across cyber-physical networks: an empirically based mathematical simulation study.. J R Soc Interface. 15(138)
Morgan JR, Schackman BR, Weinstein ZM, Walley AY, Linas BP.  2019.  Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort.. Drug Alcohol Depend. 200:34-39.
Mullangi S, Kaushal R, Ibrahim SA.  2019.  Equity in the Age of Health Care Information Technology and Innovation: Addressing the Digital Divide.. Med Care. 57 Suppl 6 Suppl 2:S106-S107.
Mullangi S, Press MJ, Ryan AM.  2019.  A delicate balance: Accountability for very high-cost patients in new payment models.. Healthc (Amst). :100366.
Mullangi S, Bhandari R, Thanaporn P, Christensen M, Kronick S, Nallamothu BK.  2020.  Perceptions of resuscitation care among in-hospital cardiac arrest responders: a qualitative analysis.. BMC Health Serv Res. 20(1):145.
Murphy SM, Morgan JR, Jeng PJ, Schackman BR.  2019.  Will converting naloxone to over-the-counter status increase pharmacy sales? Health Serv Res. 54(4):764-772.
Murphy S, Friesner DL, Rosenman R, Waslo CS, Au J, Tanne E.  2019.  Emergency department utilization among individuals with idiopathic intracranial hypertension.. Int J Health Care Qual Assur. 32(1):152-163.
Murphy SM, McCollister KE, Leff JA, Yang X, Jeng PJ, Lee JD, Nunes EV, Novo P, Rotrosen J, Schackman BR.  2018.  Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.. Ann Intern Med.
Murthy SB, Wu X, Díaz I, Parasram M, Parikh NS, Iadecola C, Merkler AE, Falcone GJ, Brown S, Biffi A et al..  2020.  Non-Traumatic Subdural Hemorrhage and Risk of Arterial Ischemic Events.. Stroke. 51(5):1464-1469.